Purchase this article with an account.
Javier Zarranz-Ventura, Ahmed Sallam, Pearse Keane, Dawn Sim, Nigel Kirkpatrick, Robert Johnston; Macular hole surgery: Does C3F8 provide better anatomical and functional outcomes than SF6 and C2F6?. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5777.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess differences in anatomical and functional outcomes when using C2F6, SF6 or C3F8 gas tamponade in macular hole surgery with 20G pars plana vitrectomy+ILM peeling+gas in a single VR unit (2005-2012).
Clinical and surgical data were prospectively entered in electronic medical records. Data collection included: demographic details, tamponade type, stage of macular hole, preoperative and postoperative BCVA, anatomical success rate by OCT and secondary cataract surgery rate.
299 eyes of 276 patients with a mean age of 69.3±8.2 years (mean±SD)(median:69) and a 1:2.5 male to female ratio were included. The type of gas employed was C2F6 in 45.8% (137/299), SF6 in 18.1% (54/299) and C3F8 in 36.1% (108/299). No differences were observed in macular hole stage and type of gas employed at baseline. Mean preoperative BCVA was significantly worse in eyes treated with C3F8 compared to SF6 and C2F6 (0.94±0.37 logMAR vs 0.82±0.28 vs 0.84±0.28, p:0.034). No significant differences in postoperative BCVA were observed between gases at any timepoint but mean BCVA change from baseline was significantly better with C3F8 than SF6 and C3F8 at 12 months (-0.51±0.38 logMAR vs -0.43±0.30 vs -0.34±0.31, p:0.037). Closure rate assessed by OCT at 1 month was 95.5% for C3F8, 97.4% for SF6 and 92.3% for C2F6. However, closed holes with persistent foveal detachment on OCT 1 month after surgery were significatively less frequent in C3F8 treated eyes compared to SF6 or C2F6 (9.1% vs 37.8% vs 38.1%, p:0.056, p:0.036, respectively). At 3rd month, no significant OCT differences were observed between gases. Cataract surgery was performed at 11.61±6.1 months in C2F6 group, 9.62±5.5 in SF6 group and 11.54±7.19 in C3F8 group, with no significant differences between groups.
In our series, C3F8 was used in poorer vision eyes, provided better anatomical outcome at 1st month as assessed by OCT analysis and showed significantly higher vision gain at 12 months than SF6 and C2F6.
This PDF is available to Subscribers Only